Finally, Coronavirus cure found in Isreal with 100% survival rate

Please check your E-mail inbox or spam to confirm.

Israeli-based Pluristem has treated its first American patient suffering from COVID-19 complications under the country’s compassionate use program, reports the Jerusalem Post.

JOIN US FOR MORE ON:
or

Read Also:

The success story has sparked widespread jubilation in Isreal, the United States and Europe with hope that accelerated manufacturing could see patients treated in what appears to be battles against a dangerous virus.

The success news comes days after a report by the company showed that six critically ill coronavirus patients in Israel who are considered high-risk for mortality were treated with Pluristem’s placenta-based cell-therapy product and survived, according to preliminary data provided by the Haifa-based company.

HEY THERE: Are you looking for a WhatsApp TV where you can find great memes, funny videos, and trending gists, even with several opportunities with cash prizes? Then look no further. LOP TV is here to bring to you this top-rated content. JOIN LOP TV now

In the US case, the patient was treated with the company’s PLX cell therapy at Holy Name Medical Center in New Jersey, where Pluristem is already running a Phase III critical limb ischemia study. Like the patients treated in Israel, this patient was critically ill with respiratory failure due to acute respiratory distress syndrome and was intubated in an intensive care unit for three weeks.

The company’s president and CEO, Yaky Yanay, said that although Pluristem is focused on a planned multinational clinical trial for the treatment of complications associated with coronavirus, it does hope to expand treatment under compassionate use in other countries at the same time.

Specifically, the US treatment was administered under the US Food and Drug Administration’s Single Patient Expanded Access Program, which is part of the US Coronavirus Treatment Acceleration Program – an emergency program aimed at getting treatments to corona patients as quickly as possible.

In Israel, the six patients were treated at three different Israeli medical centres for one week, also under a compassionate use program. They were suffering from acute respiratory failure and inflammatory complications associated with COVID-19. Four of the six patients also demonstrated the failure of other organ systems, including cardiovascular and kidney failure.
Not only had all the patients survived one week later, according to Pluristem, but four of them showed improvement in respiratory parameters and three of them are in the advanced stages of weaning from ventilators. Moreover, two of the patients with preexisting medical conditions are showing a clinical recovery in addition to the respiratory improvement

Shortly after the preliminary data was published, Dr. Jason McCarthy, a senior managing director covering the biotechnology industry at Maxim Group praised Pluristem’s efforts: “Pluristem shows the COVID-19 world the first clinical data for stem cells,” he wrote. “Pluristem is initially evaluating its cell therapy under compassionate use authorization in Israel and is also the first company to dose COVID-19 patients, as well as produce the first set of early stage data.”

The company’s results were described by Yahoo! Finance as “promising to say the least.”

“Weighing in for H.C. Wainwright, analyst Swayampakula Ramakanth calls the early data ‘encouraging’ and thinks the treatment could drive substantial gains for PSTI,” the Yahoo! Finance article reported.

PSTI is the company’s NASDAQ listing.

Pluristem’s PLX cells are “allogeneic mesenchymal-like cells that have immunomodulatory properties,” meaning they induce the immune system’s natural regulatory T cells and M2 macrophages, the company explained in a previous release. The result could be the reversal of dangerous overactivation of the immune system. This would likely reduce the fatal symptoms of pneumonia and pneumonitis (general inflammation of lung tissue).

Previous preclinical findings regarding PLX cells revealed significant therapeutic effects in animal studies of pulmonary hypertension, lung fibrosis, acute kidney injury and gastrointestinal injury.
“We are pleased with this initial outcome of the compassionate use program and committed to harnessing PLX cells for the benefit of patients and healthcare systems,” Yanay said.

Source: Dailymail Online

MASSIVE OFFER: Get your business seen by 8,000 people for just N1,000. How? See here!

Free Meta Business Management Course


DISCLAIMER: Do not pay or release sensitive financial details to any organizer/recruiter unless futher verified from your end.
Easter Hunt Sale
Easter Sale
Micheal Ace

About the Author: Micheal Ace

Simply Ace, Founding Editor & CEO of ACEworld Publishers. I'm obsessed with growth. Join me on Twitter .

5 Comments

Got a question/Suggestion? Let's talk!

LATEST OPPORTUNITIES:

🕛 Jan 30, 2023
2023 ACU Commonwealth Summer School for Talented University Students
in Scholarships | for Post Graduates

🕛 Jan 30, 2023
Apply: CERN 2023 Summer Student Internship Program
in Internships / Graduate Trainee Progs. | for Post Graduates

🕛 Jan 30, 2023
Dufil Prima Foods 2023 Graduate Trainee Programme for Young Nigerians
in Internships / Graduate Trainee Progs. | for Graduates

🕛 Jan 30, 2023
Minority Africa Fellowship for African Journalists and Storytellers 2023
in Fellowships | for Journalists

🕛 Jan 30, 2023
The Farmgate Cafe National Poetry Award 2022/2023
in Awards & Prizes | for Writers & Poets

🕛 Jan 30, 2023
The Farmgate Café National Poetry Award 2023
in Awards & Prizes | for Writers & Poets

🕛 Jan 31, 2023
American University Human Rights Essay Award 2023(Fully-funded to Washington D.C. USA)
in Awards & Prizes | for Professionals

🕛 Jan 31, 2023
Apply: West Africa Civil Society Institute (WACSI) 2023 Next Generation Internship Program
in Internships / Graduate Trainee Progs. | for Africans

🕛 Jan 31, 2023
Cheshire Prize for Literature 2022
in Awards & Prizes | for Writers & Poets

🕛 Jan 31, 2023
Cudos Foundation 2023 Grant Program for African Entrepreneurs ( $5,000 to $250,000 USD)
in Grants & Fundings | for Africans

1 2 3 4 5 6 7 8 9 10 11 12